Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy

Figure 4

The correlation between SRSF9 expression and pan-cancer clinical stage using TISIDB: (a) in ACC, (b) in KICH, (c) in KIRC, (d) in LUAD, (e) in TGCT, and (f) in LUSC. The correlation between SRSF9 expression and pan-cancer tumor grade using TISIDB: (g) in CESC, (h) in KIRC, (i) in LGG, (j) in LIHC, (k) in OV, and (l) in UCEC.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)